Organon & Co. (NYSE:OGN) Reaches New 1-Year High - Should You Buy?

Key Points

• Organon shares reached a new 52-week high of $13.70 and last traded near $13.66, with nearly 5.5 million shares changing hands.
• Analyst sentiment remains cautious: five analysts rate the stock Hold and two rate it Sell, producing a consensus “Reduce” rating and an average price target of $11.40, below the current price.
• Organon declared a quarterly dividend of $0.02 per share, equivalent to $0.08 annually and a 0.6% yield; institutional investors and hedge funds own 77.43% of the company.

Organon & Co. (NYSE:OGN - Get Free Report)'s stock price reached a new 52-week high on Thursday . The company traded as high as $13.70 and last traded at $13.66, with a volume of 5548898 shares changing hands. The stock had previously closed at $13.65.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on OGN. Piper Sandler upgraded shares of Organon & Co. from an "underweight" rating to a "neutral" rating and raised their target price for the stock from $5.00 to $14.00 in a research report on Tuesday, April 28th. BNP Paribas Exane reiterated a "neutral" rating and issued a $14.00 price target (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Finally, Weiss Ratings lowered Organon & Co. from a "hold (c)" rating to a "hold (c-)" rating in a research note on Monday, August 3rd. Five equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Reduce" and an average price target of $11.40.

Organon & Co. Stock Performance

The firm has a market capitalization of $3.59 billion, a PE ratio of 17.74, a price-to-earnings-growth ratio of 1.26 and a beta of 1.55. The company has a debt-to-equity ratio of 8.43, a quick ratio of 1.44 and a current ratio of 1.95. The company's fifty day moving average price is $13.51 and its two-hundred day moving average price is $10.68.

Organon & Co. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $0.02 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.08 annualized dividend and a yield of 0.6%. Organon & Co.'s dividend payout ratio is 10.39%.

Hedge Funds Weigh In On Organon & Co.

A number of hedge funds have recently made changes to their positions in the stock. Cetera Investment Advisers increased its position in Organon & Co. by 1.7% during the 1st quarter. Cetera Investment Advisers now owns 48,073 shares of the company's stock worth $288,000 after purchasing an additional 788 shares in the last quarter. State of Alaska Department of Revenue raised its holdings in Organon & Co. by 0.6% in the fourth quarter. State of Alaska Department of Revenue now owns 278,379 shares of the company's stock valued at $1,995,000 after buying an additional 1,570 shares during the period. Integrated Wealth Concepts LLC lifted its position in Organon & Co. by 2.8% during the third quarter. Integrated Wealth Concepts LLC now owns 58,648 shares of the company's stock valued at $626,000 after buying an additional 1,594 shares in the last quarter. Rafferty Asset Management LLC lifted its position in Organon & Co. by 8.5% during the second quarter. Rafferty Asset Management LLC now owns 23,578 shares of the company's stock valued at $228,000 after buying an additional 1,847 shares in the last quarter. Finally, Bank of Nova Scotia grew its stake in Organon & Co. by 4.6% during the third quarter. Bank of Nova Scotia now owns 44,512 shares of the company's stock worth $475,000 after buying an additional 1,947 shares during the period. Institutional investors and hedge funds own 77.43% of the company's stock.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source